Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
28.57
-0.02 (-0.07%)
Nov 19, 2025, 11:32 AM EST - Market open
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $70.57M in the quarter ending September 30, 2025, with 81,958.14% growth. This brings the company's revenue in the last twelve months to $70.79M, up 23,340.07% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$70.79M
Revenue Growth
+23,340.07%
P/S Ratio
32.80
Revenue / Employee
$495,028
Employees
143
Market Cap
2.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VRDN News
- 12 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha
- 14 days ago - Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 16 days ago - Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million - Business Wire
- 7 weeks ago - Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease - Seeking Alpha